scispace - formally typeset
X

Xiuhua Lu

Researcher at Centers for Disease Control and Prevention

Publications -  57
Citations -  7274

Xiuhua Lu is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Influenza A virus & Influenza A virus subtype H5N1. The author has an hindex of 31, co-authored 57 publications receiving 7045 citations. Previous affiliations of Xiuhua Lu include National Center for Immunization and Respiratory Diseases & United States Department of Health and Human Services.

Papers
More filters
Journal ArticleDOI

Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza Virus

TL;DR: Vaccination with recent seasonal nonadjuvanted or adjuvanted influenza vaccines induced little or no cross-reactive antibody response to 2009 H1N1 in any age group.
Journal ArticleDOI

Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays

TL;DR: A more sensitive microneutralization assay is developed to detect antibodies to avian influenza in humans and is being used for the seroepidemiologic investigations of the avian H5N1 influenza outbreak.
Journal ArticleDOI

A Mouse Model for the Evaluation of Pathogenesis and Immunity to Influenza A (H5N1) Viruses Isolated from Humans

TL;DR: This is the first demonstration of an influenza A virus that replicates systemically in a mammalian species and is neurotropic without prior adaptation and suggests a strategy of vaccine preparedness for rapid intervention in future influenza pandemics that uses antigenically related nonpathogenic viruses as vaccine candidates.
Journal ArticleDOI

Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization

TL;DR: The development and testing of an adenovirus-based influenza A virus vaccine directed against the hemagglutinin (HA) protein of the A/Vietnam/1203/2004 (H5N1) (VN/ 1203/04) strain isolated during the lethal human outbreak in Vietnam from 2003 to 2005 indicate that the rapid production and subsequent administration of recombinant adenova-based vaccines to both birds and high-risk individuals in the face of an